cellular senescence

Overview

Cellular senescence is a stable cell-state program in which cells undergo essentially irreversible growth arrest while remaining metabolically active. It is widely recognized as a hallmark of aging and a contributor to age-related tissue dysfunction, but it also appears in diverse contexts such as oxidative stress, DNA damage, oncogenic signaling, radiotherapy, metabolic disease, and chronic inflammation. Senescent cells often develop a senescence-associated secretory phenotype (SASP), characterized by the release of proinflammatory cytokines, growth factors, and other mediators that can reshape the tissue microenvironment.

Biologically, cellular senescence has a dual role. It can act as a tumor-suppressive mechanism by preventing the proliferation of damaged cells, yet persistent senescent cells can promote tissue injury, fibrosis, immune dysregulation, and disease progression. Recent work has linked senescence to mitochondrial dysfunction, mitophagy defects, p53 signaling, Wnt/β-catenin pathway changes, FOXO1-related geroprotective pathways, and inflammatory remodeling in tissues such as skin, kidney, lung, bone, lens, and reproductive organs.

Recent Publications Summary (latest 30 papers)

Recent publications continued to position cellular senescence as both a mechanistic feature of aging-related pathology and a therapeutic target. In pulmonary fibrosis, a senescence-phenotype screening campaign identified a novel tetrasubstituted cyclohexene chemotype, leading to compound 25 (UCM-17017), which reduced β-galactosidase activity in senescent human fibroblasts and selectively decreased the viability of senescent human lung adenocarcinoma cells relative to proliferative cells; the compound also showed a favorable in vivo pharmacokinetic profile and beneficial effects in a mouse model of pulmonary fibrosis 42427232Jul. In clear cell renal cell carcinoma, multi-omics analyses integrating transcriptomic, proteomic, spatial transcriptomic, and single-cell data linked higher cellular senescence levels with a suppressed immune microenvironment and worse prognosis, and machine learning approaches identified FLT1 as a key driver within a FLT1-centered network associated with disease progression 41999263Apr.

Other studies focused on how senescence can be measured and modulated in stem and progenitor cells. In human umbilical cord mesenchymal stem cells, atomic force microscopy revealed that senescent cells display increased height, surface roughness, adhesion, and elastic modulus, together with enhanced F-actin bundling and stress fiber formation, defining a senescence-associated mechanical phenotype; these changes were reversed by hypoxic intervention, and a variational autoencoder-based deep learning model was developed to quantify the age-related mechanical phenotype continuously 42127096May. In primate epididymal aging, multimodal histology and transcriptomics showed epithelial senescence alongside inflammation, fibrosis, and functional decline, while single-nucleus transcriptomics implicated principal cells and identified age-related downregulation of FOXO1; functional studies in human epididymal epithelial cells indicated that FOXO1 deficiency drives cellular senescence, and the FOXO1-LHX1 axis was described as protective against senescence 41875394Mar.

A broader aging-focused review also highlighted cellular senescence as one of several mechanisms influenced by dietary ginsenosides, alongside mitochondrial dysfunction, oxidative stress, and intestinal flora homeostasis, and discussed biosynthesis, structural modification, and AI-supported delivery strategies to improve their functional food potential 41945483Apr. Together, these publications underscore cellular senescence as a measurable phenotype, a disease-associated process, and a target for both small-molecule and cell-based interventions across fibrotic, neoplastic, and reproductive aging contexts 42427232Jul41999263Apr42127096May41875394Mar41945483Apr.

What Changes, What Holds

1. Senescence is emerging as a tractable therapeutic target in fibrosis and cancer, not just a marker of pathology
NEW DIRECTION Compound development and multi-omics work extend cellular senescence beyond its established role as a contributor to age-related tissue dysfunction and SASP-driven remodeling. The fibrosis study suggests senescent-cell vulnerability can be exploited pharmacologically, while the renal carcinoma analysis links higher senescence burden to immune suppression and poorer prognosis 42427232Jul41999263Apr. That strengthens the case for senescence as a disease-modifying axis, but it does not yet settle whether senescence is causal, compensatory, or both in these settings.

2. Senescence now has a measurable biomechanical signature and a FOXO1-linked protective axis in reproductive aging
METHOD Atomic-force and deep-learning approaches add a way to quantify senescence in stem/progenitor cells beyond conventional markers, which could improve phenotyping and screening. The primate epididymis work also sharpens the overview’s FOXO1-related geroprotective theme by placing FOXO1-LHX1 signaling in a senescence-protective role in aging epithelium 42127096May41875394Mar. These findings change how senescence is studied and monitored more than they change the core biological account.

3. Dietary ginsenosides are being positioned as senescence-modulating agents, but only as part of a broader aging network
REINFORCES The review does not overturn or extend the baseline so much as fold senescence into an already familiar cluster of aging mechanisms, including mitochondrial dysfunction and oxidative stress. Its main value is to reinforce that senescence remains a plausible intervention point in nutritional and delivery-strategy research, while leaving the mechanistic specificity and clinical relevance of such approaches unresolved 41945483Apr.